Cécile Vicier

1.7k total citations
53 papers, 808 citations indexed

About

Cécile Vicier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Cécile Vicier has authored 53 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Cécile Vicier's work include Cancer Immunotherapy and Biomarkers (17 papers), Cancer Genomics and Diagnostics (10 papers) and Renal cell carcinoma treatment (8 papers). Cécile Vicier is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Cancer Genomics and Diagnostics (10 papers) and Renal cell carcinoma treatment (8 papers). Cécile Vicier collaborates with scholars based in France, United States and Germany. Cécile Vicier's co-authors include Fabrice André, Mónica Arnedos, Stefan Michiels, Céline Lefèbvre, Hervé Bonnefoi, Sherene Loi, Stéphane Champiat, Carole Hélissey, Suzette Delaloge and Maria Vittoria Dieci and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Cécile Vicier

51 papers receiving 790 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cécile Vicier France	14	465	338	229	223	122	53	808
Yacine Barèche Belgium	14	600 1.3×	321 0.9×	197 0.9×	356 1.6×	249 2.0×	24	1.0k
Lindsey Rolfe United States	12	622 1.3×	374 1.1×	199 0.9×	174 0.8×	78 0.6×	30	856
Mónica Musteanu Spain	14	552 1.2×	415 1.2×	149 0.7×	181 0.8×	121 1.0×	32	972
Frédérique Berger France	19	517 1.1×	420 1.2×	323 1.4×	411 1.8×	69 0.6×	64	1.0k
Nadia Barraco Italy	19	495 1.1×	402 1.2×	337 1.5×	332 1.5×	130 1.1×	45	1.0k
Adam Cooper Australia	16	669 1.4×	318 0.9×	257 1.1×	303 1.4×	292 2.4×	38	1.1k
Urszula M. Polanska United Kingdom	15	432 0.9×	489 1.4×	227 1.0×	209 0.9×	104 0.9×	29	884
Alexandra S. Zimmer United States	13	815 1.8×	365 1.1×	344 1.5×	110 0.5×	192 1.6×	24	1.1k
Clémentine Le Magnen Switzerland	15	351 0.8×	455 1.3×	438 1.9×	264 1.2×	120 1.0×	22	939
Ecaterina E. Dumbrava United States	17	647 1.4×	379 1.1×	218 1.0×	194 0.9×	185 1.5×	115	1.0k

Countries citing papers authored by Cécile Vicier

Since Specialization

Citations

This map shows the geographic impact of Cécile Vicier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cécile Vicier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cécile Vicier more than expected).

Fields of papers citing papers by Cécile Vicier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cécile Vicier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cécile Vicier. The network helps show where Cécile Vicier may publish in the future.

Co-authorship network of co-authors of Cécile Vicier

This figure shows the co-authorship network connecting the top 25 collaborators of Cécile Vicier. A scholar is included among the top collaborators of Cécile Vicier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cécile Vicier. Cécile Vicier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pistilli, Barbara, Luisa Pierotti, Cécile Vicier, et al.. (2024). 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC). Annals of Oncology. 35. S357–S357. 11 indexed citations

Brandão, Mariana, Jon Zugazagoitia, Anne‐Marie C. Dingemans, et al.. (2024). Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).. Journal of Clinical Oncology. 42(16_suppl). 8583–8583. 3 indexed citations

Pegram, Mark D., Carmen Calfa, Christopher S. Chen, et al.. (2024). Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology. 42(16_suppl). TPS1121–TPS1121. 1 indexed citations

Carneiro, Benedito A., Meredith McKean, Cécile Vicier, et al.. (2024). A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2704–TPS2704. 1 indexed citations

D’Hondt, Véronique, Cécile Vicier, Jean‐Sébastien Frenel, et al.. (2023). 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01). ESMO Open. 8(1). 101378–101378. 13 indexed citations

Colomba, Émeline, Luca Campedel, Clément Dumont, et al.. (2022). Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. Cancers. 14(7). 1678–1678. 7 indexed citations

Sabatier, Renaud, Cécile Vicier, Séverine Garnier, et al.. (2022). Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology. 16(10). 2057–2070. 5 indexed citations

Champiat, Stéphane, Martin Wermke, Cécile Vicier, et al.. (2022). 732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial. Annals of Oncology. 33. S877–S878. 1 indexed citations

Guérin, Mathilde, Cécile Vicier, Jochen Walz, et al.. (2022). Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Frontiers in Immunology. 13. 984132–984132. 2 indexed citations

10.

Sabatier, Renaud, Cécile Vicier, Mathilde Guérin, et al.. (2021). Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer. Journal of Clinical Medicine. 10(6). 1272–1272. 4 indexed citations

11.

Carril-Ajuria, Lucía, Émeline Colomba, Luigi Cerbone, et al.. (2021). Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma. European Journal of Cancer. 151. 106–114. 24 indexed citations

12.

Vicier, Cécile, et al.. (2020). New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. Cancers. 12(6). 1573–1573. 28 indexed citations

13.

Barthélémy, Philippe, Clément Dumont, Brigitte Laguerre, et al.. (2020). 735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study. Annals of Oncology. 31. S574–S574. 3 indexed citations

14.

Walz, Jochen, G. Pignot, Mathilde Guérin, et al.. (2020). Metastatic hormone sensitive prostate cancer: local treatment strategies. World Journal of Urology. 39(2). 327–337. 7 indexed citations

15.

Walz, Jochen, Serge Brunelle, Jeanne Thomassin‐Piana, et al.. (2019). Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma. Frontiers in Oncology. 9. 1033–1033. 16 indexed citations

16.

Hélissey, Carole, Cécile Vicier, & Stéphane Champiat. (2016). The development of immunotherapy in older adults: New treatments, new toxicities?. Journal of Geriatric Oncology. 7(5). 325–333. 74 indexed citations

17.

Bonnet, Clément, Guillaume Beinse, Luc Cabel, et al.. (2016). ESMO ECCO 2015 : les temps forts de l’immunothérapie et des thérapies ciblées. Bulletin du Cancer. 103(6). 594–603. 2 indexed citations

18.

Onesti, Concetta Elisa, Cécile Vicier, & Fabrice André. (2015). What to expect from high throughput genomics in metastatic breast cancers?. The Breast. 24. S19–S22. 4 indexed citations

19.

Albigès, Laurence, Aïcha Goubar, Véronique Scott, et al.. (2014). Chk1 as a new therapeutic target in triple-negative breast cancer. The Breast. 23(3). 250–258. 46 indexed citations

20.

Tabouret, Émeline, Maryline Barrié, Cécile Vicier, et al.. (2012). Association of carcinoid tumor and low grade glioma. World Journal of Surgical Oncology. 10(1). 236–236. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact